I.M. Sechenov First Moscow State Medical University
sechenov.ruLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
137
Active
25
Phase 3
1
Total enrollment
39,832
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Standart medical treatment | — | — | — | — | — | 1 | |
| Rifaximin | — | — | — | — | — | 1 |
Next readouts
- 2026-06
- 2026-09-30
Top conditions
- Heart Failure6
- Coronary Artery Disease6
- Soft Tissue Atrophy5
- COVID-195
- Prostate Cancer5
- Quality of Life4
- Knee Osteoarthritis4
- Cardiovascular Diseases4
Frequently asked questions about I.M. Sechenov First Moscow State Medical University
- How many clinical trials does I.M. Sechenov First Moscow State Medical University have on ClinicalTrials.gov?
- I.M. Sechenov First Moscow State Medical University is listed as the lead sponsor on 137 clinical trials in ClinicalTrials.gov, 25 of which are currently active (recruiting, enrolling, or ongoing).
- How many of I.M. Sechenov First Moscow State Medical University's trials are in Phase 3?
- 1 of I.M. Sechenov First Moscow State Medical University's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does I.M. Sechenov First Moscow State Medical University focus on?
- I.M. Sechenov First Moscow State Medical University's most-studied conditions on ClinicalTrials.gov are Heart Failure, Coronary Artery Disease, Soft Tissue Atrophy, COVID-19, Prostate Cancer.
- When are I.M. Sechenov First Moscow State Medical University's next clinical trial readouts?
- I.M. Sechenov First Moscow State Medical University has 2 upcoming primary-completion readouts tracked here; the soonest is “Metabolomics in the Diagnosis and Treatment of Asthma in Children”, expected around 2026-06.